NCT06632886 AI-Assisted Non-Contrast CT for Multi-Cancer Screening
| NCT ID | NCT06632886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guo ShiWei |
| Condition | Lung Cancers |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000,000 participants |
| Start Date | 2024-10-07 |
| Primary Completion | 2026-10-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000,000 participants in total. It began in 2024-10-07 with a primary completion date of 2026-10-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening. The study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.
Eligibility Criteria
Inclusion Criteria: 1. Subject is able and willing to provide informed consent and sign an informed consent form. 2. Subject has undergone an abdominal or chest non-contrast CT scan. Exclusion Criteria: 1. Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer; 2. Subject has any medical condition that contraindicates high-resolution MRI/CT/Endoscopy; 3. Subject cannot be followed up or is participating in other clinical trials.
Contact & Investigator
Jin Gang, M.D.
STUDY CHAIR
Department of general surgery, Changhai Hospital
Frequently Asked Questions
Who can join the NCT06632886 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06632886 currently recruiting?
Yes, NCT06632886 is actively recruiting participants. Contact the research team at lilly_wang@126.com for enrollment information.
Where is the NCT06632886 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06632886 clinical trial?
NCT06632886 is sponsored by Guo ShiWei. The principal investigator is Jin Gang, M.D. at Department of general surgery, Changhai Hospital. The trial plans to enroll 1,000,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.